Carisbamate

Carisbamate
Carisbamate
Systematic (IUPAC) name
(S)-2-O-carbamoyl-1-o-chlorophenyl-ethanol
Clinical data
Pregnancy cat.  ?
Legal status  ?
Identifiers
CAS number 194085-75-1
ATC code N03AX19
PubChem CID 9942577
ChemSpider 8118189 YesY
UNII P7725I9V3Z YesY
Chemical data
Formula C9H10ClNO3 
Mol. mass 215.633 g/mol
SMILES eMolecules & PubChem
 YesY(what is this?)  (verify)

Carisbamate (YKP 509, proposed trade name Comfyde) is an experimental anticonvulsant drug under development by Johnson & Johnson Pharmaceutical Research and Development. In 1998, the compound was in-licensed from SK Corp. (currently Life Science Business Division of SK Holdings), a South Korean company. A phase II clinical trial in the treatment of partial seizures demonstrated that the compound has efficacy in the treatment of partial seizures and a good safety profile. Since late 2006, the compound has been undergoing a large multicenter phase III clinical trial for the treatment of partial seizures. Its mechanism of action is unknown.[1][2]

On October 24, 2008, Johnson & Johnson announced that it had submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for carisbamate.[3] Carisbamate has received provisional approval by the FDA to be marketed under the brand name of Comfyde. However, on August 21, 2009, Johnson & Johnson reported that the FDA had failed to give marketing approval.

A double-blind, placebo-controlled trial cf carisbamate in 323 patients with migraine failed to demonstrate that the active drug was more effective than placebo.[4] However, carisbamate was well tolerated at doses up to 600 mg/day.

References

  1. ^ Rogawski MA (2006). "Diverse mechanisms of antiepileptic drugs in the development pipeline". Epilepsy Res 69 (3): 273–294. doi:10.1016/j.eplepsyres.2006.02.004. PMC 1562526. PMID 16621450. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1562526. 
  2. ^ Novak GP, Kelley M, Zannikos P, Klein B (2007). "Carisbamate (RWJ-333369)". Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 4 (1): 106–109. doi:10.1016/j.nurt.2006.11.016. PMID 17199023. 
  3. ^ "Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Carisbamate" (Press release). Johnson & Johnson. 2008-10-24. http://www.drugs.com/nda/comfyde_081024.html. Retrieved 2008-11-02. 
  4. ^ Cady RK, Mathew N, Diener HC, Hu P, Haas M, Novak GP; Study Group. (2009). "Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial". Headache 49 (2): 216–226. doi:10.1111/j.1526-4610.2008.01326.x. PMID 19222595. 
v · d · eAnticonvulsants (N03)
GABAA receptor agonist
Other GABA agents
Carbonic anhydrase inhibitor
Channel blockers
Primarily sodium
Carbamazepine# • Eslicarbazepine acetate • Oxcarbazepine • Oxitriptyline • Rufinamide
Primarily calcium
Unknown/ungrouped
Channel openers
Potassium
Retigabine
Indirect GABA agents

GABA transaminase inhibitor: Valproic acid# (Sodium valproate & Valproate semisodium) • Valpromide • Valnoctamide • Valproate pivoxil

GABA reuptake inhibitor: Tiagabine
Gabapentin • Pregabalin • Progabide • Tolgabide • Vigabatrin
Unknown/multiple/
unsorted
Emylcamate • Felbamate • Meprobamate • Carisbamate
Propionates
#WHO-EM. ‡Withdrawn from market. Clinical trials: †Phase III. §Never to phase III

M: CNS

anat(n/s/m/p/4/e/b/d/c/a/f/l/g)/phys/devp

noco(m/d/e/h/v/s)/cong/tumr, sysi/epon, injr

proc, drug(N1A/2AB/C/3/4/7A/B/C/D)


Stub icon This anticonvulsant-related article is a stub. You can help Wikipedia by expanding it.